{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+-+saline&page=5",
    "query": {
      "intervention": "Placebo - saline",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 3542,
    "total_pages": 355,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+-+saline&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+-+saline&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-18T20:39:21.542Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02424708",
      "title": "Phase IIb Study of Intranasal Glutathione in Parkinson's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "Reduced Glutathione 100mg",
          "type": "DRUG"
        },
        {
          "name": "Reduced Glutathione 200mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bastyr University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2015-04",
      "completion_date": "2016-04",
      "has_results": false,
      "last_update_posted_date": "2016-06-24",
      "last_synced_at": "2026-11-18T20:39:21.542Z",
      "location_count": 2,
      "location_summary": "Kenmore, Washington • Seattle, Washington",
      "locations": [
        {
          "city": "Kenmore",
          "state": "Washington"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02424708"
    },
    {
      "nct_id": "NCT02669121",
      "title": "Efficacy and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-like Particle Vaccine in Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "NoV Placebo-matching Saline",
          "type": "BIOLOGICAL"
        },
        {
          "name": "NoV GI.1/GII.4 Bivalent VLP Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 4748,
      "start_date": "2016-06-14",
      "completion_date": "2018-06-16",
      "has_results": true,
      "last_update_posted_date": "2021-06-10",
      "last_synced_at": "2026-11-18T20:39:21.542Z",
      "location_count": 1,
      "location_summary": "Great Lakes, Illinois",
      "locations": [
        {
          "city": "Great Lakes",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02669121"
    },
    {
      "nct_id": "NCT03691935",
      "title": "Erector Spinae Plane Block (ESPB): in Patients Undergoing Surgery Through a Flank or Anterior Subcostal Incision.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Nephrectomy",
        "Partial Nephrectomy",
        "Incision Site Discomfort"
      ],
      "interventions": [
        {
          "name": "Ropivacaine",
          "type": "DRUG"
        },
        {
          "name": "Normal saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Milton S. Hershey Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 20,
      "start_date": "2018-09-28",
      "completion_date": "2024-02-02",
      "has_results": true,
      "last_update_posted_date": "2025-02-10",
      "last_synced_at": "2026-11-18T20:39:21.542Z",
      "location_count": 1,
      "location_summary": "Hershey, Pennsylvania",
      "locations": [
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03691935"
    },
    {
      "nct_id": "NCT04210115",
      "title": "Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Esophageal Squamous Cell Carcinoma (ESCC)",
        "Gastroesophageal Junction Carcinoma (GEJC)",
        "Esophageal Adenocarcinoma (EAC)"
      ],
      "interventions": [
        {
          "name": "pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "5-FU",
          "type": "DRUG"
        },
        {
          "name": "radiotherapy",
          "type": "RADIATION"
        },
        {
          "name": "leucovorin",
          "type": "DRUG"
        },
        {
          "name": "levoleucovorin",
          "type": "DRUG"
        },
        {
          "name": "oxaliplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 703,
      "start_date": "2020-02-28",
      "completion_date": "2026-06-26",
      "has_results": false,
      "last_update_posted_date": "2026-10-30",
      "last_synced_at": "2026-11-18T20:39:21.542Z",
      "location_count": 19,
      "location_summary": "Long Beach, California • Columbus, Georgia • Westwood, Kansas + 16 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Columbus",
          "state": "Georgia"
        },
        {
          "city": "Westwood",
          "state": "Kansas"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04210115"
    },
    {
      "nct_id": "NCT00182143",
      "title": "PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Critical Illness",
        "Deep Venous Thrombosis"
      ],
      "interventions": [
        {
          "name": "LMWH (Fragmin, dalteparin)",
          "type": "DRUG"
        },
        {
          "name": "Unfractionated Heparin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "McMaster University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3659,
      "start_date": "2006-05",
      "completion_date": "2010-06",
      "has_results": false,
      "last_update_posted_date": "2011-01-10",
      "last_synced_at": "2026-11-18T20:39:21.542Z",
      "location_count": 4,
      "location_summary": "Rochester, Minnesota • St Louis, Missouri • Providence, Rhode Island + 1 more",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Providence",
          "state": "Rhode Island"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00182143"
    },
    {
      "nct_id": "NCT00412035",
      "title": "Botox Injection for Lower Extremity Lengthening and Deformity Correction Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Unequal Length of Limbs; Congenital",
        "Lower Extremity Deformities, Congenital"
      ],
      "interventions": [
        {
          "name": "Botulinum toxin A injection",
          "type": "DRUG"
        },
        {
          "name": "saline injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shriners Hospitals for Children",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "5 Years to 21 Years"
      },
      "enrollment_count": 125,
      "start_date": "2007-01",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2014-12-23",
      "last_synced_at": "2026-11-18T20:39:21.542Z",
      "location_count": 4,
      "location_summary": "Wilmington, Delaware • Honolulu, Hawaii • Portland, Oregon + 1 more",
      "locations": [
        {
          "city": "Wilmington",
          "state": "Delaware"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00412035"
    },
    {
      "nct_id": "NCT03099863",
      "title": "Cytoscopic Antibiotic Irrigant to Reduce Postoperative Urinary Tract Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Urinary Tract Infections"
      ],
      "interventions": [
        {
          "name": "Cystoscopic Fluid containing Neosporin G. U. Irrigant",
          "type": "DRUG"
        },
        {
          "name": "Cystoscopy",
          "type": "PROCEDURE"
        },
        {
          "name": "Cystoscopic Fluid/Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "MetroHealth Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 242,
      "start_date": "2016-04",
      "completion_date": "2020-06",
      "has_results": true,
      "last_update_posted_date": "2021-12-30",
      "last_synced_at": "2026-11-18T20:39:21.542Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03099863"
    },
    {
      "nct_id": "NCT00333515",
      "title": "Pharmacokinetic (PK) and Safety Study of Plasma-derived Human Butyrylcholinesterase Administered Intravenously",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers",
        "Chemical Terrorism",
        "Chemical Warfare"
      ],
      "interventions": [
        {
          "name": "Human Butyrylcholinesterase (HuBChE) derived from human plasma",
          "type": "DRUG"
        },
        {
          "name": "Placebo: Normal saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 28,
      "start_date": "2007-01-01",
      "completion_date": "2008-08-01",
      "has_results": false,
      "last_update_posted_date": "2021-05-05",
      "last_synced_at": "2026-11-18T20:39:21.542Z",
      "location_count": 1,
      "location_summary": "Lenexa, Kansas",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00333515"
    },
    {
      "nct_id": "NCT00448864",
      "title": "Efficacy Study of Recombinant Protein (Ecallantide) to Reduce Blood Loss During Primary Coronary Bypass Grafting or Valve Repair/Replacement",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Blood Loss, Surgical"
      ],
      "interventions": [
        {
          "name": "Ecallantide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 75,
      "start_date": "2007-05-01",
      "completion_date": "2008-08-01",
      "has_results": true,
      "last_update_posted_date": "2019-06-25",
      "last_synced_at": "2026-11-18T20:39:21.542Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 8 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00448864"
    },
    {
      "nct_id": "NCT06577233",
      "title": "Superior Hypogastric Nerve Plexus Block With Bupivacaine After Robotic Resection of Endometriosis",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Endometriosis"
      ],
      "interventions": [
        {
          "name": "Bupivacaine Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Normal saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 65 Years · Female only"
      },
      "enrollment_count": 60,
      "start_date": "2024-08-28",
      "completion_date": "2025-08-31",
      "has_results": false,
      "last_update_posted_date": "2025-08-18",
      "last_synced_at": "2026-11-18T20:39:21.542Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06577233"
    }
  ]
}